ALN-CC5: Phase I/II ongoing

Alnylam said it will narrow its development program for ALN-CC5 to target poor responders to Soliris eculizumab and PNH patients who require Soliris sparing. The company was developing ALN-CC5 for a broader population of treatment-naive and Soliris-treated PNH patients. Alnylam said it based the decision on preliminary evidence from the open-label third part of a 3-part, U.K. Phase I/II trial evaluating single and multiple ascending doses of subcutaneous ALN-CC5 to treat PNH. The company previously reported data from the double-blind first and second parts of the trial (see BioCentury, July 13, 2015 & Dec. 14, 2015). ...